crbpFor those wondering why Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares are presently taking a 25% nosedive, look no further than The Street blogger Adam Feuerstein’s ominous “crash landing” prediction today calling it early that the biotech stock has a major plunge waiting for it in the wings.

The blogger just received compelling intel that has him freshly tentative on the stock as he urges the rest of biotech investors to heed caution as well.

Currently, Feurstein is guarding the identity of his “most reliable and skeptical healthcare investor,” but he offers this valuable morsel of information about the manager behind the biotech bearish prediction: “Most recently, he was short Mast Therapeutics Inc (NYSEMKT:MSTX), CytRx Corporation (NASDAQ:CYTR), NewLink Genetics Corp (NASDAQ:NLNK), Chiasma Inc (NASDAQ:CHMA) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) before they all blew up.”

Call this mystery investor a psychic when it comes to predicting the onset of a biotech stock’s downfall. Maybe he’s the next Joseph from the old-age tale of a man who had a knack for interpreting dreams as clues for events that would then unfold. Whatever the reason for Feurstein’s undisclosed source’s prowess in making on-point calls, one thing is for sure: the blogger believes in the magnitude of the implications that this investor is suddenly short Corbus.

Why is it that this oracle of the healthcare stock-verse has stopped rooting for the firm? The blogger indicates the source’s bearish theory arises from the fact that resunab, CRBP’s rare inflammatory disease drug designed as potential treatment for cystic fibrosis, systemic sclerosis, dermatomyositis, and lupus, which happens to be the sole drug in the firm’s research pipeline, simply “doesn’t work.”

For a market that deems resunab “a real drug,” Feurstein says his source “says he knows better” and for this reason is rocking the bullish boat of analysts who contributed in CRBP’s stock price skyrocketing from $1.50 per share back in January to close to $10 per share at the start of October.

Clearly, now more than ever, all eyes are peeled to the close of the quarter, when the firm will release a top-line data read-out from a mid-stage clinical trial of resunab. Then, we will see if Feurstein’s tried-and-true healthcare investor and his bearish biotech crystal ball are to be trusted once more.

On the ratings front, Corbus Pharmaceuticals  been the subject of a number of recent research reports. In a report issued on October 4, Cantor analyst Elemer Piros initiated coverage with a Buy rating on CRBP and a price target of $17, which represents a potential upside of 146% from where the stock is currently trading. Separately, on September 19, Aegis’ Robert LeBoyer maintained a Buy rating on the stock and has a price target of $12.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Elemer Piros and Robert LeBoyer have a total average return of 7.5% and -19.2% respectively. Piros has a success rate of 44% and is ranked #648 out of 4190 analysts, while LeBoyer has a success rate of 27% and is ranked #3826.

Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its product Resunab, is a novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression.